Drugs in ATC Class S01HA

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Up to S01H - LOCAL ANESTHETICS

Drugs in ATC Class: S01HA - Local anesthetics

Tradename	Generic Name
GOPRELTO	cocaine hydrochloride
NUMBRINO	cocaine hydrochloride
PLIAGLIS	lidocaine; tetracaine
SYNERA	lidocaine; tetracaine
KOVANAZE	oxymetazoline hydrochloride; tetracaine hydrochloride
TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride

Market dynamics and patent landscape for ATC Class S01HA (Local anesthetics)

Last updated: April 25, 2026

What is the market structure for ATC S01HA (Local anesthetics)?

ATC S01HA covers topical ophthalmic local anesthetics (drug class used for surface anesthesia in eye procedures). Market dynamics follow a tight pattern: procedure-driven demand, low dosing volumes per patient, and intense generic competition once patents expire.

Demand drivers

• Outpatient ophthalmic procedures: cataract pre-op/adjunct use, minor procedures, and diagnostic interventions where clinicians apply topical corneal/lid anesthesia.
• Clinician workflow: adoption favors products with predictable onset and tolerability, short preparation time, and stable formulation.
• Regulatory and procurement: hospital formularies and government tenders often accelerate substitution to lower-cost generics.

Competitive dynamics

• Reference brand lock-in is time-limited. Once patents end (and exclusivity windows lapse), price compression is rapid.
• Formulation differentiation matters inside a mature API environment. Companies sustain pricing through:
  • buffered vs unbuffered formulations
  • preservative system choices
  • viscosity/vehicle changes that affect comfort and duration
  • device-adjunct packaging (single-use) and distribution channel control

Pricing pressure by lifecycle stage

• Post-approval peak: strongest net pricing before follow-on entrants.
• Pre-expiry: branded products remain dominant in ophthalmic clinics that standardize peri-procedure kits.
• Post-expiry: multi-source generic entry forces margin dilution and shifts purchasing to tenders.

Which APIs within S01HA dominate and how does that shape patents?

S01HA ophthalmic local anesthetics class usage is dominated by a narrow set of actives that drive the patent landscape:

• Tetracaine (base and salts)
• Proparacaine (hydrochloride)
• Lidocaine (and related ophthalmic local anesthetic formulations)

This narrow API set drives a common patent pattern across geographies:

1. Old composition-of-matter is long expired for most actives.
2. The remaining enforceable value often sits in formulation, use claims (specific indications or procedural methods), and manufacturing/process details.
3. Second-generation patents tend to cluster around stability, pH/buffer systems, preservative compatibility, and patient-comfort characteristics (duration, local tolerability).

How does the patent landscape typically behave across S01HA?

Dominant claim clusters

Patent filings in this therapeutic slice typically fall into four buckets:

Claim cluster	What it protects	Why it matters in S01HA
Composition (specific salt/formulation)	Exact formulation with defined ratios/pH/preservative	Sustains market differentiation even after API expiry
Method of use (procedures/indications)	Application timing or procedural setting	Useful for arguing non-equivalence vs generic labeling
Manufacturing/process	Specific steps improving stability/sterility	Can block “same-formulation” workarounds
Device/packaging (single-use/delivery)	Container and dosing system	Often reduces cross-price substitution in institutional channels

Litigation and “evergreening” pattern

S01HA products frequently show:

• short enforcement windows after first approval cycles
• dense continuation practice close to expiry (formulation improvements)
• regulatory exclusivity overlap with patent term adjustments in key markets

The upshot for investors and planners: pipeline value is concentrated in line extensions, not raw API invention.

What are the major markets where S01HA monetizes, and how do exclusivity dynamics differ?

The economic center of gravity for ophthalmic topical local anesthetics aligns to where procedure volume and tendering intensity are highest.

Key geography dynamics

• United States
  • High generic penetration once Orange Book-listed exclusivities/patents expire.
  • Hatch-Waxman frameworks often generate fast “Paragraph IV” challenges for branded formulations.
  • Labeling and method-of-use claims can become the battleground.
• European Union
  • Substitution occurs under national tender systems; some markets retain brand presence longer when formularies are conservative.
  • Generics use marketing authorization pathways with bioequivalence and formulation equivalence.
• United Kingdom (post-Brexit)
  • Similar tender-driven dynamics to Europe, with company-specific formulary retention patterns.
• Japan and Canada
  • Typically slower generic penetration than the US on timeline, but eventual substitution remains dominant.

Tender-driven substitution effect

In ophthalmic settings, procurements often specify:

• concentration
• preservative system (or preservative-free requirement)
• packaging format (single-dose vs multi-dose) These specs determine whether a generic is an “effective substitute” from a procurement standpoint, even if the active ingredient is the same.

Where does patent coverage persist longest: formulation vs method-of-use?

In S01HA, formulation patents tend to outlive pure API coverage because they are easiest to differentiate without changing active ingredient. Method-of-use claims persist where clinicians follow a distinctive workflow tied to the product.

Formulation is the main remaining moat

Formulation patents often include:

• specific pH windows
• buffer agents
• preservative type and concentration
• tonicity targets
• vehicle viscosity modifiers

Because ophthalmic tolerance is sensitive, small formulation changes can carry regulatory and clinical relevance. That is why formulation claims still drive infringement analysis even when the actives are old.

Method-of-use survives via labeling leverage

Method-of-use claims survive only when:

• the branded labeling specifies a narrow or procedure-linked use
• generics replicate the instruction set closely enough to infringe
• the method claims are drafted with concrete steps (timing, dosing, sequence)

In practice, generic labeling tends to mirror broad indications, reducing the scope for method-of-use enforcement unless the branded claim is narrow.

What is the actionable patent landscape approach for S01HA?

For business planning and investment screening, treat S01HA as a dossier-level formulation battlefield, not an API race.

Practical mapping framework

1. Identify the exact marketed ophthalmic anesthetic products by active, strength, and formulation type (including preservative system).
2. Map patents by geography:
   • US: Orange Book and related prosecution families
   • EP/UK: national validations tied to EPO family members
   • CA/JP: local patent registrations and listing practices
3. Classify claims:
   • formulation composition
   • method of use tied to procedures
   • process/manufacture
4. Time the “switch” points:
   • first marketed product approval date
   • patent term expiry (including PTA where applicable)
   • any pediatric exclusivity and supplementary protection certificates where relevant

Signals that point to enforceable value

• patents that repeatedly cite:
  • pH and buffering systems
  • preservative compatibility and ocular comfort
  • single-use stability or sterilization method
• continuation families with overlapping claim sets
• claim language that ties tolerability or onset duration metrics to the specific formulation

What are likely patent expiry and entry timing outcomes for S01HA?

S01HA outcomes are typically:

• Rapid generic entry after the last enforceable formulation or method claim expires.
• Late-stage “product-by-product” enforcement, where brand owners defend only their strongest SKUs.
• Shelf-market share shifts driven by procurement specifications (preservative-free and single-dose can delay substitution).

A realistic planning view is that each marketed SKU can have:

• distinct patent families (not one uniform family across all strengths)
• different expiry dates due to filing timelines and claim drafting
• different tender leverage due to preservative/packaging differentiation

What does this mean for R&D strategy in S01HA?

Build around differentiation that can be claimed

R&D value is strongest when it targets protectable features:

• preservative-free or reduced-irritant systems
• buffered pH systems optimized for corneal tolerance
• vehicle viscosity/comfort improvements that support new formulation claims
• single-dose packaging stability and shelf-life improvements that can be framed in process and formulation claims

Avoid strategies that depend on known actives without a patentable formulation payload

If the program relies on the same generic-equivalent formulation features, the value erodes quickly and the patent estate is thin.

Key Takeaways

• S01HA is structurally procedure-driven and tender-influenced, leading to fast price compression after patent or exclusivity lapses.
• The patent moat is primarily formulation-specific (pH/buffer/preservative/vehicle) and secondarily method-of-use or process.
• Market outcomes across major regions follow the same pattern: multiplicity of generics once enforceable SKU-level patents expire, with slower displacement only when the branded product is preservative-free and/or single-dose and is locked into procurement specs.
• For investment and R&D prioritization, treat S01HA as a SKU-level dossier and claim mapping problem, not an API-level landscape exercise.

FAQs

1) Is ATC S01HA’s patent risk mostly API-related or formulation-related?

Formulation-related. Most actives are mature; enforceable differentiation usually sits in specific formulation attributes and related process claims.

2) Why do procurement specifications matter for S01HA despite generic availability?

Because tenders often require exact concentration, preservative system, and packaging format, which can make some generics non-substitutable in institutional buying even when the active matches.

3) What claim types most often survive in S01HA after generic entry accelerates?

Composition/formulation patents and closely drafted method-of-use claims that map to specific labeled procedural steps.

4) What is the fastest path to market share loss for a branded S01HA product?

Expiry of the last SKU-relevant formulation patent paired with multi-source generic tenders that replicate the required preservative/packaging requirements.

5) What R&D directions create the best chance of new enforceable value in S01HA?

Preservative-free or reduced-irritant systems, buffered pH formulations, and vehicle/packaging strategies that can be translated into clear claim language.

References

[1] World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. https://www.whocc.no/atc_ddd_index/ (accessed 2026-04-25)